Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate

A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuasa-Shibasaki, Erina, Ishii, Sumiyasu, Matsumoto, Shunichi, Tomaru, Takuya, Horiguchi, Kazuhiko, Osaki, Aya, Ozawa, Atsushi, Shibusawa, Nobuyuki, Satoh, Tetsurou, Yamada, Masanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849551/
https://www.ncbi.nlm.nih.gov/pubmed/29225247
http://dx.doi.org/10.2169/internalmedicine.9036-17
Descripción
Sumario:A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid supplementation decreased her calcium level to a normal range, indicating that hypercalcemia was induced by adrenal insufficiency. It was suggested that she was suffering from MPA-induced adrenal insufficiency, but hypocortisolemia was being compensated by a high dose of MPA; hypocortisolemia and hypercalcemia then became evident after MPA treatment was discontinued.

Ejemplares similares